Advertisement

Topics

Times Not to Forget Radiotherapy When Treating Patients With Lymphoma.

08:00 EDT 1st April 2019 | BioPortfolio

Summary of "Times Not to Forget Radiotherapy When Treating Patients With Lymphoma."

Radiation therapy remains an important component of lymphoma treatment. It has evolved with improvements in technology and a better understanding of how to successfully integrate it into lymphoma treatment. There are specific clinical presentations where omission of radiation therapy could adversely affect patient outcome and should not be overlooked. Radiation therapy may serve an important role as primary treatment, as a component of combined modality therapy, as adjuvant therapy to maximize local control, and as an important component of salvage therapy for relapsed or primary refractory lymphoma and in the successful palliation of lymphoma. This review identifies those clinical presentations where the use of radiation therapy should not be overlooked or should at least be considered.

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of oncology practice
ISSN: 1935-469X
Pages: 167-172

Links

DeepDyve research library

PubMed Articles [29542 Associated PubMed Articles listed on BioPortfolio]

Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy.

The standard treatment of waldeyer's ring DLBCL remains controversial. This retrospective study was designed to evaluate the role of consolidation radiotherapy (RT) in patients with stage I/II diffuse...

A prospective, multicentre study of involved-field radiotherapy with autologous stem cell transplantation for patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (ALLG HDNHL04/TROG 03.03).

The role of involved-field radiotherapy (IFRT) with autologous stem cell transplantation (ASCT) for lymphomas remains uncertain.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-lin...

Radiotherapy Should Be Part of a Multidisciplinary Discussion for Most Patients With Lymphoma.

New tools of the trade: parsing out the role of radiotherapy for early-stage diffuse large B-cell lymphoma.

Clinical Trials [10781 Associated Clinical Trials listed on BioPortfolio]

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-Cell Lymphoma

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in tr...

RADVAX™ FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve re...

Low-Dose Radiation Therapy in Treating Patients With Follicular Non-Hodgkin's Lymphoma

RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. It is not yet known which regimen of low-dose radiation therapy is more effective in treating follicular non-Hodg...

Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma

RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy i...

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-...

Medical and Biotech [MESH] Definitions

B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.

Mistakes committed in the preparations for radiotherapy, including errors in positioning of patients, alignment radiation beams, or calculation of radiation doses.

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).

The total amount of radiation absorbed by tissues as a result of radiotherapy.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article